Obesity

Your daily dose of the clinical news you may have missed.

Compared to the lowest intake of AS-rich food and beverages, the highest intake was associated with a 59% higher risk of developing MetS, according to new findings.

While the FDA's preliminary evaluation has not surfaced evidence of a link, the agency says it "cannot definitively rule out that a small risk may exist," and so will continue research.

Your daily dose of the clinical news you may have missed.

Semaglutide was associated with a lower risk of first-time and recurrent suicidal ideations in patients with obesity or overweight or T2D, according to new study.

Angela Fitch, MD, president of the Obesity Medicine Association, details what to look forward to this year in terms of obesity management.

Individuals with "lean NAFLD" may be at similar risk of NASH, cirrhosis, nonliver cancer, and death as as those with NAFLD and overweight or obesity, authors say.

President of the Obesity Medicine Association discusses how clinician perspectives on obesity and obesity treatment are changing for the better.

In an open letter to the public, Lilly decries use of tirzepatide products Mounjaro and Zepbound for nonmedical purposes and warns of counterfeit formulations.

Findings underscore the importance of preventive measures and management of risk factors associated with CKD in adolescents with elevated BMI, report researchers.

Angela Fitch, MD, discusses the importance of clinician education in addressing obesity with patients.

President of the Obesity Medicine Association discusses a recent joint statement from the OMA and 4 other organizations calling for inclusion of patients with obesity in drug research.

Your daily dose of the clinical news you may have missed.

Angela Fitch, MD, president of the Obesity Medicine Association discusses key pharmaceutical and research developments in obesity medicine in 2023.

Your daily dose of the clinical news you may have missed.

The American Board of Obesity Medicine says annual first-time certificates now exceed those for cardiology, pulmonology, and medical oncology.

The task force recommends clinicians provide or refer children and adolescents with a high BMI to intensive, comprehensive behavioral interventions.

Study participants randomized to placebo for 1 year after 36 weeks on tirzepatide had mean weight regain of 14% vs augmented loss among those who continued on the medication.

While incretin-based antiobesity medications are the optimal treatment for some, there are other less costly approaches that can support weight loss success, this author says.

The dual GIP/GLP-1 mimetic is available by prescription for adults with obesity or overweight with comorbidities and Lilly is offering a savings card program.

The 5 leading advocacy groups said the safety of people with obesity is at risk and called on the FDA to change clinical trial inclusion requirements and expedite labeling changes.

Your daily dose of the clinical news you may have missed.

An obesity specialist discusses the importance of using a weight-first approach when educating patients about obesity's role in the development and worsening of hypertension.

"Primary care physicians... really are like the quarterbacks" for initiating multidisciplinary care for CKM syndrome, says Dr Chiadi Ndumele.

Absolute risk assessment for CVD remains the corner-stone of clinical primary prevention efforts. The new AHA prediction models expand that foundation.

Your daily dose of the clinical news you may have missed.

Patients with obesity and hypertension need to be aggressively treated in order to decrease their risk of cardiovascular complications, says Dr Jonathan Parker, President of the Alabama Obesity Society.

Managing cardiovascular-kidney-metabolic syndrome on a population-wide basis requires that social determinants of health be treated like any other risk factor, according to Ndumele.

From highest percentage of children with obesity to lowest percentage of adults with hypercholesterolemia, see how obesity hits home in our new slideshow.

Dr Chiadi Ndumele explains the need for the more comprehensive and also nuanced qualitative approach to estimating long-term CVD risk.